Is NCT07549958 recruiting in Orange, CA?

Yes, NCT07549958 is currently recruiting participants at its Orange, CA location. This pancreatic cancer clinical trial is actively enrolling qualified participants.

How do I join the pancreatic cancer clinical trial in Orange?

To join this clinical trial in Orange, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Orange clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Pancreatic Cancer Clinical Trial in Orange, CA

About This Pancreatic Cancer Study in Orange

This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disease.

Sponsor: University of California, Irvine

Who Can Participate

Inclusion Criteria

Age ≥ 18 years old

Provision of a signed and dated ICF by the participant

Has a diagnosis of histologically or cytologically confirmed metastatic, recurrent, or locally advanced PDAC

Receiving a gemcitabine-based treatment regimen for a minimum of 2 and a maximum of 4 cycles without radiographic progression (ie SD or better).

Measurable disease per RECIST 1.1

Adequate organ (hematologic, hepatic, renal) function defined below:

Hemoglobin ≥ 9.0 g/dL (transfusion is allowed)

Platelets ≥ 100,000/mcL (transfusion is allowed)

ANC ≥ 1500/mcL

AST/ALT ≤ 3 x ULN (≤ 5 x ULN is allowable in cases of liver metastasis or Gilbert's Syndrome)

Serum bilirubin ≤ 1.5 x ULN

Serum albumin ≥ 3.0 g/dL

Serum creatinine ≤ 1.5 x ULN OR creatinine clearance \> 60 mL/min

ECOG PS 0-2

2 lines or less of prior treatment. Prior curative intent treatment (surgery and, if given in the adjuvant setting, systemic therapy and/or radiation) is permitted, regardless of time to recurrence, and does not constitute a line of therapy. This includes participants with residual disease after surgery, who received systemic therapy, chemoembolization, or radiotherapy.

Exclusion Criteria

Uncontrolled significant clinical illness

Clinically significant autoimmune disease

Major surgery within 4 weeks of the first dose of registration

Known prior malignancy active within the previous 3 years, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

Concomitant use of statin therapy (to be discontinued 2 weeks prior to the start of C1D1).

For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HbsAg) are eligible.

Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

Patients with a known history of HIV.

Known active metastases in the central nervous system (unless stable by brain imaging studies for at least 1 month after last treatment)

Patients with QT interval corrected by Fridericia's formula (QTcF) \> 470 msec for both men and women on screening ECG are excluded.

A woman of childbearing potential who has a positive pregnancy test prior to initiating study treatment.

Breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Screening visit through 5 months after the last dose of study treatment.

Medicines known to inhibit or induce either CYP2C8, CYP2C9, or CYP3A4

History of prior organ or stem cell transplant.

Has an active infection requiring systemic therapy. Systemic treatment used prophylactically is allowable.

Patients who are unable to swallow or retain oral medication.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Orange?

Yes, this clinical trial (NCT07549958) has an active research site in Orange, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Cancer Treatment Options in Orange, CA

If you're searching for pancreatic cancer treatment options in Orange, CA, this clinical trial (NCT07549958) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Orange research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic cancer clinical trials near you to find additional studies recruiting in your area.

Pancreatic Cancer Clinical Trial in Orange, CA

Expert Care in Orange

IRB Approved

No-Cost Care

Apply for This Orange Location

Why Participate?

Simple Process